ArticlePloS one2025
New chalcone compound exhibits microrna-mediated anticancer properties in glioblastoma.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Advances in quercetin-based therapeutics for breast cancer: natural, synthetic, and nanotechnology-driven approaches.Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTherapy-resistant glioblastoma constitutes the most lethal adult brain malignancy, bearing extremely poor patients' prognosis. Combinational therapies are accompanied by severe side effects and significant financial burden, highlighting the urgent need for alternative, low toxicity treatments. This study sought to investigate the therapeutic efficacy of a new synthetic chalcone molecule, SHG-44, and its cellular mechanistic actions in U87MG and U251MG glioblastoma cell line models.
methodsThe effect of SHG-44 on glioblastoma cell viability, clonogenic survival, and cell migration was assessed using in vitro functional assays. Cellular reactive oxygen species levels were quantified to investigate oxidative stress induced by SHG-44. The induction of apoptosis by SHG-44 was examined through nuclear fragmentation analysis and acridine orange/ethidium bromide staining. Small RNA-sequencing was performed to explore the regulatory effects of SHG44 on microRNA expression. The pharmacokinetic and pharmacodynamic properties of SHG-44 were evaluated through in-silico analysis.
resultsCell viability assays demonstrated that SHG-44 significantly reduced cell viability in glioblastoma cells, with half-maximal inhibitory concentration of 70.39ΜΜ and 64.19ΜΜ in U87MG and U251MG cells, respectively. In line with these findings, a colony formation assay revealed a significant impairment of glioblastoma cells' clonogenic survival. SHG-44 effects on cell migration demonstrated a substantial abrogation of cell migration at 100ΜΜ SHG-44 within both glioblastoma cell lines. Cellular reactive oxygen species quantification showed a significant increase of ROS at 40ΜΜ SHG-44 concentrations within U87MG cells and a non-significant elevation of ROS within U251MG cells. Nuclear fragmentation and acridine orange/ethidium bromide staining demonstrated that SHG-44 mediated cytotoxicity in U87MG and U251MG through apoptosis induction. Small RNA-sequencing analysis demonstrated that SHG-44 could regulate various cellular pathways through microRNA expression modulation in glioblastoma cell models. Further in-silico analysis of the pharmacokinetics and pharmacodynamics properties of SHG-44 demonstrated that the compound possessed sufficient absorption, distribution, potential to pass through the blood brain barrier, and low oral toxicity characteristics.
conclusionTaken together these findings suggested the potential anti-cancer properties of the newly synthesized chalcone compound, SHG-44 and its dynamic implications in glioblastoma therapeutic management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.